[Edaily Reporter Park Sun-Yeop ] OCI Holdings Company Ltd. is trading higher after successfully returning to profitability in the second quarter of this year and announcing plans to expand its polysilicon and wafer production capacity. According to MP Doctor on the 24th, OCI Holdings Company Ltd.(010060)was trading at 253,500 won as of 9:19 a.m. today, up 6,500 won (2.63%) from the previous trading day. OCI Holdings Company Ltd. announced the previous day that its consolidated operating profit for the second quarter was 108 billion won, marking a return to profitability from a loss of 80.3 billion won in the same period last year. Revenue increased by 31.8% to 1.0232 trillion won, and net income stood at 60.6 billion won. This marks three consecutive quarters of operating profit since the fourth quarter of last year. This is due to the sale of a 500-megawatt (MW) solar project by its U.S. subsidiary, OCI Energy, as well as consistent improvements in the performance of its major subsidiaries. OCI Holdings Company Ltd. plans to expand its polysilicon production capacity from the current 35,000 metric tons per year to 70,000 metric tons by 2029 to meet demand from the U.S. artificial intelligence (AI) infrastructure and space industries. Its Vietnamese wafer subsidiary, NeoSilicon Technology, also plans to increase its production capacity to 11.5 gigawatts (GW) during the same period. Hwang Seong-hyun, an analyst at EUGENE INVESTMENT & SECURITIES, stated in a report released today, “The establishment of a supply chain for the space industry is taking shape thanks to new long-term supply contracts and decisions to expand production capacity,” and maintained a “Buy” rating and a target price of 400,000 won.
KYUNGDONGNAVIEN(009450)has completed its domestic production system for core heat pump components and is accelerating its push into the electric heating market. With the production of outdoor units no…
Global cosmetics Original Design Manufacturer (ODM) company COSMAX, INC.(192820)announced on the 24th that it has added a dedicated “Import/Export Support” menu within its e-Biz system—which serves as…
Hanmi Pharmaceutical ( HanmiPharm(128940)) is utilizing its proprietary artificial intelligence (AI) platform to identify novel, innovative drugs for obesity and next-generation muscle-building therap…